200487
β-Amyloid Oligomer Inhibitor, K01-162
The β-Amyloid Oligomer Inhibitor, K01-162 controls the biological activity of β-Amyloid Oligomer.
别名:
β-Amyloid Oligomer Inhibitor, K01-162, AβO Inhibitor, K01-162
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles, protect from light
color
white to off-white
solubility
DMSO: 50 mg/mL
shipped in
ambient
Quality Level
General description
A cell permeable, fluorene compound that destabilizes the aggregation state of β-amyloid oligomers (AβO) by directly targeting AβO and inhibiting AβO binding to synapses. It displays full MC65 protection at 125 nM, with an EC50 of 80 nM in a neuronal MC65 culture-based assay, and substantially reduces intraneuronal AβO in primary neuronal culture at concentrations between 100 nM and 10 µM. Furthermore, it is shown to significantly reduce amyloid levels by 50% compared with control in vivo in a 5xFAD mice cerebral Aβ amyloidosis model when dosed intracerebroventricularly without apparent toxicity.
Packaging
Packaged under inert gas
Other Notes
Hong, H-S., et al. 2010. Neurobiol. Aging31, 1690.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Dusan Mrdenovic et al.
ACS chemical neuroscience, 12(3), 531-541 (2021-01-23)
Alzheimer's disease (AD) is characterized by progressive neurodegeneration associated with amyloid β (Aβ) peptide aggregation. The aggregation of Aβ monomers (AβMs) leads to the formation of Aβ oligomers (AβOs), the neurotoxic Aβ form, capable of permeating the cell membrane. Here
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持